AU2017312660B2 - Methods of treating eosinophilic esophagitis - Google Patents

Methods of treating eosinophilic esophagitis Download PDF

Info

Publication number
AU2017312660B2
AU2017312660B2 AU2017312660A AU2017312660A AU2017312660B2 AU 2017312660 B2 AU2017312660 B2 AU 2017312660B2 AU 2017312660 A AU2017312660 A AU 2017312660A AU 2017312660 A AU2017312660 A AU 2017312660A AU 2017312660 B2 AU2017312660 B2 AU 2017312660B2
Authority
AU
Australia
Prior art keywords
patient
week
corticosteroid
oral
less
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2017312660A
Other languages
English (en)
Other versions
AU2017312660A1 (en
Inventor
Gail COMER
Brian Meltzer
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Adare Pharma Solutions Inc
Original Assignee
Adare Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Adare Pharmaceuticals Inc filed Critical Adare Pharmaceuticals Inc
Publication of AU2017312660A1 publication Critical patent/AU2017312660A1/en
Application granted granted Critical
Publication of AU2017312660B2 publication Critical patent/AU2017312660B2/en
Priority to AU2023233115A priority Critical patent/AU2023233115A1/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/006—Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Electronic Switches (AREA)
AU2017312660A 2016-08-18 2017-08-18 Methods of treating eosinophilic esophagitis Active AU2017312660B2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2023233115A AU2023233115A1 (en) 2016-08-18 2023-09-20 Methods of treating eosinophilic esophagitis

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201662376703P 2016-08-18 2016-08-18
US62/376,703 2016-08-18
US201762461317P 2017-02-21 2017-02-21
US62/461,317 2017-02-21
US201762489292P 2017-04-24 2017-04-24
US62/489,292 2017-04-24
PCT/US2017/047474 WO2018035393A1 (en) 2016-08-18 2017-08-18 Methods of treating eosinophilic esophagitis

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU2023233115A Division AU2023233115A1 (en) 2016-08-18 2023-09-20 Methods of treating eosinophilic esophagitis

Publications (2)

Publication Number Publication Date
AU2017312660A1 AU2017312660A1 (en) 2019-03-07
AU2017312660B2 true AU2017312660B2 (en) 2023-06-29

Family

ID=61197039

Family Applications (2)

Application Number Title Priority Date Filing Date
AU2017312660A Active AU2017312660B2 (en) 2016-08-18 2017-08-18 Methods of treating eosinophilic esophagitis
AU2023233115A Pending AU2023233115A1 (en) 2016-08-18 2023-09-20 Methods of treating eosinophilic esophagitis

Family Applications After (1)

Application Number Title Priority Date Filing Date
AU2023233115A Pending AU2023233115A1 (en) 2016-08-18 2023-09-20 Methods of treating eosinophilic esophagitis

Country Status (11)

Country Link
US (7) US10105315B2 (enExample)
EP (1) EP3500264A4 (enExample)
JP (3) JP6929934B2 (enExample)
KR (3) KR20230167146A (enExample)
AU (2) AU2017312660B2 (enExample)
CA (1) CA3034264A1 (enExample)
NZ (1) NZ750754A (enExample)
RU (1) RU2766577C2 (enExample)
TW (2) TWI777515B (enExample)
UY (1) UY37370A (enExample)
WO (1) WO2018035393A1 (enExample)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7608693B2 (en) 2006-10-02 2009-10-27 Regeneron Pharmaceuticals, Inc. High affinity human antibodies to human IL-4 receptor
EP2482822B1 (en) 2009-10-01 2018-08-01 Adare Pharmaceuticals, Inc. Orally administered corticosteroid compositions
KR102576903B1 (ko) 2012-09-07 2023-09-13 리제너론 파아마슈티컬스, 인크. Ｉｌ-4ｒ 길항제 투여로 아토피성 피부염을 치료하는 방법
TWI755763B (zh) 2013-06-04 2022-02-21 美商再生元醫藥公司 藉由投與il-4r抑制劑以治療過敏及增強過敏原-特異之免疫療法的方法
TWI634900B (zh) 2013-07-11 2018-09-11 再生元醫藥公司 藉由投與ｉｌ－４ｒ抑制劑治療嗜酸性食道炎的方法
WO2015034678A2 (en) 2013-09-06 2015-03-12 Aptalis Pharmatech, Inc. Corticosteroid containing orally disintegrating tablet compositions for eosinophilic esophagitis
KR102927870B1 (ko) 2014-02-28 2026-02-19 리제너론 파아마슈티컬스, 인크. Ｉｌ-4ｒ 길항제의 투여에 의한 피부 감염의 치료 방법
TWI777515B (zh) 2016-08-18 2022-09-11 美商愛戴爾製藥股份有限公司 治療嗜伊紅性食道炎之方法
US11771743B2 (en) 2016-09-01 2023-10-03 Regeneron Pharmaceuticals, Inc. Methods for preventing or treating allergy by administering an IL-4R antagonist
US20200381097A1 (en) * 2018-02-21 2020-12-03 Adare Pharmaceuticals Us, L.P. Methods of treating eosinophilic esophagitis
MA52624A (fr) 2018-05-13 2021-03-24 Regeneron Pharma Méthodes de traitement de la dermatite atopique par administration d'un inhibiteur de l'il-4r
US10562930B1 (en) 2018-08-31 2020-02-18 Praxis Precision Medicines, Inc. Salts and crystal forms of GABAA positive allosteric modulator
US11672959B2 (en) * 2019-01-18 2023-06-13 Intersect Ent, Inc. Expandable member systems and methods for drug delivery
SG11202109002XA (en) 2019-03-21 2021-09-29 Regeneron Pharma Combination of il-4/il-13 pathway inhibitors and plasma cell ablation for treating allergy
CN113811240A (zh) 2019-05-02 2021-12-17 因特尔赛克特耳鼻喉国际有限责任公司 球囊扩张装置
EP4010373A1 (en) 2019-08-05 2022-06-15 Regeneron Pharmaceuticals, Inc. Methods for treating atopic dermatitis by administering an il-4r antagonist
AU2020325021B2 (en) 2019-08-05 2024-05-30 Regeneron Pharmaceuticals, Inc. Methods for treating allergy and enhancing allergen-specific immunotherapy by administering an IL-4R antagonist
US11188680B2 (en) 2019-09-20 2021-11-30 International Business Machines Corporation Creating research study corpus
US11106813B2 (en) * 2019-09-20 2021-08-31 International Business Machines Corporation Credentials for consent based file access
US11327665B2 (en) 2019-09-20 2022-05-10 International Business Machines Corporation Managing data on volumes
US11321488B2 (en) 2019-09-20 2022-05-03 International Business Machines Corporation Policy driven data movement
US11443056B2 (en) 2019-09-20 2022-09-13 International Business Machines Corporation File access restrictions enforcement
US11328089B2 (en) 2019-09-20 2022-05-10 International Business Machines Corporation Built-in legal framework file management
KR20220074915A (ko) * 2019-10-01 2022-06-03 엘로디 파마슈티컬스, 엘.피. 호산구성 식도염을 치료하고 칸디다증을 감소시키는 방법
US11075010B1 (en) * 2020-03-19 2021-07-27 Insight RX, Inc. Pharmacology model optimization based on distributed data acquisition
WO2021216917A1 (en) * 2020-04-22 2021-10-28 Topical Sinus Therapeutics, Inc. Targeted administration to the oropharynx of viscous or dry powder fluticasone propionate and related corticosteroids for the treatment of eosinophilic esophagitis (eoe)
IL298257A (en) * 2020-05-22 2023-01-01 Regeneron Pharma Methods for treating eosinophilic esophagitis by administering an il-4r inhibitor
JP2024515299A (ja) * 2021-04-20 2024-04-08 エロディ ファーマシューティカルズ，エル．ピー． 食道狭窄の治療方法
WO2022232104A1 (en) * 2021-04-26 2022-11-03 Praxis Precision Medicines, Inc. Methods of treatment with neuroactive steroids
EP4091615A1 (en) * 2021-05-20 2022-11-23 Dr. Falk Pharma Gmbh Orodispersible effervescent tablet comprising budesonide for use in the treatment of eosinophilic esophagitis
CN119997959A (zh) * 2022-07-28 2025-05-13 威斯康星州医药大学股份有限公司 用于治疗反流的缓释口服福沙那韦制剂
WO2025128792A1 (en) * 2023-12-13 2025-06-19 Ellodi Pharmaceuticals, L.P. Methods of treating eosinophilic esophagitis and depleting mast cell

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090149433A1 (en) * 2007-11-13 2009-06-11 Meritage Pharma, Inc. Compositions for the treatment of inflammation of the gastrointestinal tract
US20140303131A1 (en) * 2009-10-01 2014-10-09 Stephen Perrett Orally administered corticosteroid compositions
US20160206627A1 (en) * 2013-09-06 2016-07-21 Adare Pharmaceuticals, Inc. Corticosteroid containing orally disintegrating tablet compositions for eosinophilic esophagitis

Family Cites Families (100)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1170188A (en) 1967-09-15 1969-11-12 Bayer Ag N-trityl-imidazoles and salts and uses thereof
SE378109B (enExample) 1972-05-19 1975-08-18 Bofors Ab
DE2260384C3 (de) 1972-12-09 1979-11-29 Hoechst Ag, 6000 Frankfurt Oral zu applizierendes Corticosteroid-Präparat
US4080448A (en) 1974-11-13 1978-03-21 Mirsky Louis H Method of treating cellular stress
BE887518A (fr) 1980-02-15 1981-08-13 Glaxo Group Ltd Cartothioates d'androstanes
SE8004580L (sv) 1980-06-19 1981-12-20 Draco Ab Farmaceutisk beredning
CY1359A (en) 1981-02-02 1987-08-07 Schering Corp Aromatic heterocyclic esters of steroids, their preparation and pharmaceutical compositions containing them
GB8630913D0 (en) 1986-12-24 1987-02-04 Glaxo Group Ltd Pharmaceutical compositions
US5446070A (en) 1991-02-27 1995-08-29 Nover Pharmaceuticals, Inc. Compositions and methods for topical administration of pharmaceutically active agents
ZA892859B (en) 1988-04-22 1989-12-27 Advanced Polymer Systems Inc Porous particles in preparations involving immiscible phases
GB9002375D0 (en) 1990-02-02 1990-04-04 Pfizer Ltd Triazole antifungal agents
US5278175A (en) 1990-02-02 1994-01-11 Pfizer Inc. Triazole antifungal agents
GR1001529B (el) 1990-09-07 1994-03-31 Elmuquimica Farm Sl Μέ?οδος για την λήψη νέων 21-εστέρων της 16-17-ακετάλης της πρ να-1,4-διενο-3,20-διόνης.
CA2101773A1 (en) 1991-01-31 1992-08-01 Toyoichi Tanaka Interpenetrating-polymer network phase-transition gels
PT735884E (pt) 1993-12-20 2000-09-29 Minnesota Mining & Mfg Formulacoes de aerossol de flunisolida
SE9501384D0 (sv) 1995-04-13 1995-04-13 Astra Ab Process for the preparation of respirable particles
GB9517062D0 (en) 1995-08-18 1995-10-25 Scherer Ltd R P Pharmaceutical compositions
US5863910A (en) * 1996-01-12 1999-01-26 Bolonick; Joel Treatment of chronic inflammatory disorders of the gastrointestinal tract
DE19606151C2 (de) 1996-02-20 1999-05-12 Losan Pharma Gmbh Ibuprofen-Brausezubereitung sowie Verfahren zur Herstellung derselben
CA2258159C (en) 1996-06-14 2006-03-21 Kyowa Hakko Kogyo Co., Ltd. Intraorally rapidly disintegrable tablet
US8071128B2 (en) 1996-06-14 2011-12-06 Kyowa Hakko Kirin Co., Ltd. Intrabuccally rapidly disintegrating tablet and a production method of the tablets
SE9604486D0 (sv) 1996-12-05 1996-12-05 Astra Ab Novel formulation
GB9707934D0 (en) 1997-04-18 1997-06-04 Danbiosyst Uk Improved delivery of drugs to mucosal surfaces
RO118174B1 (ro) 1997-08-21 2003-03-28 Aventis Pharma Deutschland Gmbh Lac de unghii şi utilizarea acestuia
DE69901938T3 (de) 1998-03-06 2012-08-02 Aptalis Pharma S.R.L. Schnell zerfallende tablette
FR2781156B1 (fr) 1998-07-20 2001-06-29 Lafon Labor Composition pharmaceutique destinee notamment a la prevention et au traitement des radiomucites et des chimiomucites
US6596298B2 (en) 1998-09-25 2003-07-22 Warner-Lambert Company Fast dissolving orally comsumable films
ES2388425T5 (es) 1999-04-23 2020-02-12 Leo Pharma As Composición farmacéutica no acuosa para uso dérmico para tratar la psoriasis que comprende una vitamina D, un corticoesteroide y un componente disolvente
CA2317999C (en) 1999-09-11 2004-11-09 Glaxo Group Limited Pharmaceutical formulation of fluticasone propionate
KR100446101B1 (ko) 2000-12-07 2004-08-30 주식회사 삼양사 수난용성 약물의 서방성 제형 조성물
US20030050312A1 (en) 2001-03-12 2003-03-13 Hjorth Thyge Borup Novel tablets and capsules and a process for its preparation
EP1418945A2 (en) 2001-03-13 2004-05-19 Angiotech Pharmaceuticals, Inc. Micellar drug delivery vehicles and uses thereof
US6872405B2 (en) 2001-05-10 2005-03-29 Yamanouchi Pharmaceutical Co., Ltd. Quick-disintegrating tablet in buccal cavity and manufacturing method thereof
ATE333269T1 (de) 2001-05-10 2006-08-15 Astellas Pharma Inc In der mundhöhle schnell zerfallende tabletten und prozess zu deren herstellung
US6656493B2 (en) 2001-07-30 2003-12-02 Wm. Wrigley Jr. Company Edible film formulations containing maltodextrin
FR2831820B1 (fr) 2001-11-05 2004-08-20 Ethypharm Sa Comprime orodispersible presentant une grande homogeneite et son procede de preparation
US20030206978A1 (en) 2001-11-29 2003-11-06 Bob Sherwood Agglomerated particles including an active agent coprocessed with silicified microcrystalline cellulose
US20040009212A1 (en) 2002-01-30 2004-01-15 Pharma Power Biotec Co. Ltd. Mucoadhesive thermoresponsive medicament-carrier composition
JP4173670B2 (ja) 2002-03-08 2008-10-29 旭化成ファーマ株式会社 口腔内崩壊製剤
PL220850B1 (pl) 2002-05-03 2016-01-29 Janssen Pharmaceutica Nv Kopolimer dwublokowy, kompozycja zawierająca składnik aktywny i jej zastosowanie oraz sposób jej wytwarzania
WO2004021997A2 (en) 2002-09-06 2004-03-18 Microbia, Inc. Inhibitors of fungal invasion
WO2004023984A2 (en) 2002-09-13 2004-03-25 Smith C Steven Novel composition and method for treatment of upper respiratory conditions
US7731947B2 (en) 2003-11-17 2010-06-08 Intarcia Therapeutics, Inc. Composition and dosage form comprising an interferon particle formulation and suspending vehicle
EP1595533B1 (en) 2003-01-21 2010-01-06 Nippon Shinyaku Co., Ltd. Tablet quickly melting in oral cavity
CA2512559A1 (en) 2003-01-31 2004-08-12 Orexo Ab A rapid-acting pharmaceutical composition
US20040208833A1 (en) 2003-02-04 2004-10-21 Elan Pharma International Ltd. Novel fluticasone formulations
US8012505B2 (en) 2003-02-28 2011-09-06 Alk-Abello A/S Dosage form having a saccharide matrix
US20040265375A1 (en) 2003-04-16 2004-12-30 Platteeuw Johannes J. Orally disintegrating tablets
US20050009848A1 (en) 2003-07-10 2005-01-13 Icn Pharmaceuticals Switzerland Ltd. Use of antivirals against inflammatory bowel diseases
US20060134054A1 (en) 2003-12-19 2006-06-22 Council Of Scientific And Industrial Research Polymer composition for pH dependent dissolution behavior and process for preparation thereof
CA2558393A1 (en) 2004-03-10 2005-09-22 Schering Aktiengesellschaft Compositions comprising drospirenone molecularly dispersed
US8545881B2 (en) 2004-04-19 2013-10-01 Eurand Pharmaceuticals, Ltd. Orally disintegrating tablets and methods of manufacture
EP1634586B1 (en) 2004-09-09 2007-02-14 Laboratorio Medinfar-Produtos Farmaceuticos, S.A. Fast water-dispersible domperidone tablets
US20070020330A1 (en) 2004-11-24 2007-01-25 Medpointe Healthcare Inc. Compositions comprising azelastine and methods of use thereof
US20060292099A1 (en) 2005-05-25 2006-12-28 Michael Milburn Treatment of eye disorders with sirtuin modulators
WO2007028247A1 (en) 2005-09-09 2007-03-15 University Of Manitoba Fast-disintegrating epinephrine tablets for buccal or sublingual administration
US8679545B2 (en) 2005-11-12 2014-03-25 The Regents Of The University Of California Topical corticosteroids for the treatment of inflammatory diseases of the gastrointestinal tract
US8324192B2 (en) 2005-11-12 2012-12-04 The Regents Of The University Of California Viscous budesonide for the treatment of inflammatory diseases of the gastrointestinal tract
US8497258B2 (en) * 2005-11-12 2013-07-30 The Regents Of The University Of California Viscous budesonide for the treatment of inflammatory diseases of the gastrointestinal tract
JP2007158225A (ja) 2005-12-08 2007-06-21 Canon Inc 露光装置
CN1985799B (zh) 2005-12-19 2011-11-09 量子高科（北京）研究院有限公司 口腔崩解制剂的制备方法
EP1978939A2 (en) 2005-12-27 2008-10-15 Jubilant Organosys Limited Mouth dissolving pharmaceutical composition and process for preparing the same using a high amount of silicon dioxine
US20080260655A1 (en) 2006-11-14 2008-10-23 Dov Tamarkin Substantially non-aqueous foamable petrolatum based pharmaceutical and cosmetic compositions and their uses
EP1958613A1 (en) 2007-02-15 2008-08-20 Polichem S.A. Dermal film-forming liquid formulations for drug release to skin
EP2148659A2 (en) 2007-04-13 2010-02-03 Somaxon Pharmaceuticals, Inc. Low-dose doxepin formulations
US20150231156A1 (en) * 2007-11-13 2015-08-20 Meritage Pharma, Inc. Corticosteroid compositions
US20090123551A1 (en) 2007-11-13 2009-05-14 Meritage Pharma, Inc. Gastrointestinal delivery systems
US20100216754A1 (en) * 2007-11-13 2010-08-26 Meritage Pharma, Inc. Compositions for the treatment of inflammation of the gastrointestinal tract
US9050368B2 (en) 2007-11-13 2015-06-09 Meritage Pharma, Inc. Corticosteroid compositions
KR20100119539A (ko) 2007-12-10 2010-11-09 유란드, 인코포레이티드 다이펜하이드라민을 포함하는 경구 분해성 정제
CN105496978A (zh) 2007-12-21 2016-04-20 阿代尔制药股份有限公司 替马西泮的口腔崩解片组合物
JP2009173552A (ja) 2008-01-21 2009-08-06 Lion Corp 胃腸薬
US20090264392A1 (en) 2008-04-21 2009-10-22 Meritage Pharma, Inc. Treating eosinophilic esophagitis
ME01256B (me) 2008-07-21 2013-06-20 Dr Falk Pharma Gmbh Farmaceutska formulacija za lečenje gornjeg digestivnog trakta
MX2011001487A (es) 2008-08-08 2011-03-30 Mcneil Ppc Inc Uso de sucralosa como agente granulante.
DK2328553T3 (da) 2008-08-20 2020-08-24 Univ California Corticosteroider til behandling af inflammatoriske sygdomme i mave-tarm-kanalen
EP2381835A1 (en) 2009-01-15 2011-11-02 Nestec S.A. Methods of diagnosing and treating dysphagia
EP2398470A4 (en) 2009-02-23 2013-03-06 Aptalis Pharmatech Inc CONTROLLED RELEASE COMPOSITIONS COMPRISING A PROTON PUMP INHIBITOR
WO2010144865A2 (en) 2009-06-12 2010-12-16 Meritage Pharma, Inc. Methods for treating gastrointestinal disorders
BR112012005117A2 (pt) 2009-09-07 2016-05-03 Dbv Tech método de tratamento de esofagite eosinofílica
NZ600123A (en) 2009-11-30 2015-04-24 Aptalis Pharmatech Inc Compressible-coated pharmaceutical compositions and tablets and methods of manufacture
ES2894936T3 (es) 2010-06-24 2022-02-16 Viropharma Biologics Llc Métodos de tratamiento para la inflamación del esófago
MX365568B (es) 2010-12-02 2019-06-07 Adare Pharmaceuticals Inc Granulos de dispersion rapida, comprimidos de disolucion oral y metodos.
AU2012208912B2 (en) 2011-01-18 2016-03-03 Holland Bloorview Kids Rehabilitation Hospital Method and device for swallowing impairment detection
CA2824392C (en) 2011-01-28 2020-05-12 Nestec S.A. Apparatuses and methods for diagnosing swallowing dysfunction
KR20140113667A (ko) * 2011-12-16 2014-09-24 아토픽스 테라퓨릭스 리미티드 호산구성 식도염의 치료를 위한 ｃｒｔｈ2 길항제 및 양성자 펌프 저해제의 조합
JP2015522653A (ja) 2012-07-26 2015-08-06 ルピン・リミテッドＬｕｐｉｎ Ｌｉｍｉｔｅｄ プロトンポンプ阻害剤の医薬組成物
TWI634900B (zh) 2013-07-11 2018-09-11 再生元醫藥公司 藉由投與ｉｌ－４ｒ抑制劑治療嗜酸性食道炎的方法
DK2886108T4 (da) 2013-12-23 2023-01-30 Dr Falk Pharma Gmbh Optimeret farmaceutisk formulering til behandling af inflammatoriske ændringer af øsofagus
US10294517B2 (en) 2014-03-17 2019-05-21 Children's Hospital Medical Center Genetic test for determining susceptibility for eosinophilic esophagitis
US10176301B2 (en) 2014-09-11 2019-01-08 Meritage Pharma, Inc. Systems, methods, and software for providing a patient-reported outcome measure of dysphagia patients with eosinophilic esophagitis
US9980975B2 (en) * 2015-01-22 2018-05-29 Ems S.A. Dosage forms containing fluticasone propionate for the treatment of inflammatory conditions of the esophagus
US10869592B2 (en) 2015-02-23 2020-12-22 Uroviu Corp. Handheld surgical endoscope
KR20240052871A (ko) 2016-04-27 2024-04-23 애브비 인코포레이티드 항-il-13 항체를 이용한 il-13 활성이 유해한 질환의 치료 방법
US10076494B2 (en) 2016-06-16 2018-09-18 Dexcel Pharma Technologies Ltd. Stable orally disintegrating pharmaceutical compositions
TWI777515B (zh) 2016-08-18 2022-09-11 美商愛戴爾製藥股份有限公司 治療嗜伊紅性食道炎之方法
US20200381097A1 (en) 2018-02-21 2020-12-03 Adare Pharmaceuticals Us, L.P. Methods of treating eosinophilic esophagitis
KR20220074915A (ko) 2019-10-01 2022-06-03 엘로디 파마슈티컬스, 엘.피. 호산구성 식도염을 치료하고 칸디다증을 감소시키는 방법
WO2022020464A1 (en) 2020-07-21 2022-01-27 Ellodi Pharmaceuticals, L.P. Modified release rapidly disintegrating compositions of proton pump inhibitors
JP2024515299A (ja) 2021-04-20 2024-04-08 エロディ ファーマシューティカルズ，エル．ピー． 食道狭窄の治療方法

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090149433A1 (en) * 2007-11-13 2009-06-11 Meritage Pharma, Inc. Compositions for the treatment of inflammation of the gastrointestinal tract
US20140303131A1 (en) * 2009-10-01 2014-10-09 Stephen Perrett Orally administered corticosteroid compositions
US20160206627A1 (en) * 2013-09-06 2016-07-21 Adare Pharmaceuticals, Inc. Corticosteroid containing orally disintegrating tablet compositions for eosinophilic esophagitis

Also Published As

Publication number Publication date
AU2023233115A1 (en) 2023-10-12
WO2018035393A1 (en) 2018-02-22
TWI728172B (zh) 2021-05-21
US20190008760A1 (en) 2019-01-10
TW202206079A (zh) 2022-02-16
JP2021178866A (ja) 2021-11-18
US10105315B2 (en) 2018-10-23
JP6929934B2 (ja) 2021-09-01
JP7526143B2 (ja) 2024-07-31
KR20190039769A (ko) 2019-04-15
TW201808304A (zh) 2018-03-16
JP2019528272A (ja) 2019-10-10
UY37370A (es) 2018-01-02
RU2019105805A (ru) 2020-09-18
KR20210095973A (ko) 2021-08-03
US12059494B2 (en) 2024-08-13
KR20230167146A (ko) 2023-12-07
CA3034264A1 (en) 2018-02-22
US11896710B2 (en) 2024-02-13
US20200368147A1 (en) 2020-11-26
US20210346278A1 (en) 2021-11-11
EP3500264A4 (en) 2020-04-29
TWI777515B (zh) 2022-09-11
US20180133145A1 (en) 2018-05-17
RU2019105805A3 (enExample) 2020-11-13
US11026887B2 (en) 2021-06-08
US20230414498A1 (en) 2023-12-28
NZ750754A (en) 2023-02-24
RU2766577C2 (ru) 2022-03-15
JP2024164004A (ja) 2024-11-26
AU2017312660A1 (en) 2019-03-07
EP3500264A1 (en) 2019-06-26
US20250170057A1 (en) 2025-05-29
US11684571B2 (en) 2023-06-27
US20210275438A1 (en) 2021-09-09

Similar Documents

Publication Publication Date Title
US12059494B2 (en) Methods of treating eosinophilic esophagitis
US12109196B2 (en) Non-sedating dexmedetomidine treatment regimens
US20250255884A1 (en) Corticosteroid containing orally disintegrating tablet compositions for eosinophilic esophagitis
US20250302808A1 (en) Dexmedetomidine treatment regimens
JP2019528272A5 (enExample)
US12268777B2 (en) Compositions and methods for treating eosinophilic disorders
US20220257597A1 (en) Methods of Administering Elagolix
NZ790981A (en) Methods of treating eosinophilic esophagitis
Dellon et al. Fluticasone Propionate Orally Disintegrating Tablet (APT-1011) for Eosinophilic Esophagitis: Randomized Controlled Trial Short title: A Phase 2b Study of APT-1011 to Treat EoE

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired
NA Applications received for extensions of time, section 223

Free format text: AN APPLICATION TO EXTEND THE TIME FROM 18 AUG 2024 TO 18 JUL 2025 IN WHICH TO PAY A RENEWAL FEE HAS BEEN FILED

NB Applications allowed - extensions of time section 223(2)

Free format text: THE TIME IN WHICH TO PAY A RENEWAL FEE HAS BEEN EXTENDED TO 18 JUL 2025